Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  nolatrexed dihydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-10 of 10 for your search:
Start Over
Phase II Study of Continuous-Infusion AG-337 (a Thymidylate Synthase Inhibitor) for Adenocarcinoma of the Pancreas (Summary Last Modified 09/95)
Phase: Phase II
Type: Treatment
Status: Completed
Age: over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: AG-337-006, NCI-V95-0632
Phase II Study of AG337 (a Thymidylate Synthase Inhibitor) as a 5-Day Continuous Infusion for Primary Hepatocellular Carcinoma (Summary Last Modified 08/95)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AG-337-008, NCI-V95-0633
Phase II Study of AG337 (a Thymidylate Synthase Inhibitor) as a 5-Day Continuous Infusion for Prostate Cancer (Summary Last Modified 06/97)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AG-337-007, NCI-V95-0634
Phase II Study of AG337 by 5-Day Continuous Infusion in Adenocarcinoma of the Colon (Summary Last Modified 01/96)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor:
Protocol IDs: AG-337-009, NCI-V95-0635
Phase II Study of AG-337 (a Thymidylate Synthase Inhibitor) as a 5-Day Continuous Infusion for Squamous Cell Carcinoma of the Head and Neck (Summary Last Modified 08/95)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AG-337-004, NCI-V95-0636
Phase II Study of AG337 (a Thymidylate Synthase Inhibitor) as a 5-Day Continuous Infusion for Stage IIIB/IV Nonsmall Cell Lung Cancer (Summary Last Modified 06/97)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AG-337-005, NCI-V95-0637
Phase II Study of AG337 (a Thymidylate Synthase Inhibitor) Administered as a 5-Day Continuous Infusion for Locally Advanced or Metastatic Hepatocellular Carcinoma (Summary Last Modified 02/98)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AG-337-015, NCI-V96-0946
Phase I Study of Continuous-Infusion AG337, a Thymidylate Synthase Inhibitor, plus CDDP for Advanced Solid Tumors (Summary Last Modified 02/98)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AG-337-013, NCI-V96-0874
Start Over